Boston Partners trimmed its position in HCA Healthcare Inc (NYSE:HCA) by 4.6% during the first quarter, Holdings Channel reports. The institutional investor owned 41,385 shares of the company’s stock after selling 1,988 shares during the period. Boston Partners’ holdings in HCA Healthcare were worth $5,396,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently bought and sold shares of the company. Oregon Public Employees Retirement Fund boosted its position in shares of HCA Healthcare by 16,494.3% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 11,119,359 shares of the company’s stock worth $89,000 after purchasing an additional 11,052,352 shares in the last quarter. Norges Bank purchased a new stake in shares of HCA Healthcare during the 4th quarter worth $359,391,000. Canada Pension Plan Investment Board boosted its position in shares of HCA Healthcare by 111.5% during the 4th quarter. Canada Pension Plan Investment Board now owns 1,614,102 shares of the company’s stock worth $200,858,000 after purchasing an additional 850,902 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of HCA Healthcare by 33.6% during the 1st quarter. Janus Henderson Group PLC now owns 2,368,547 shares of the company’s stock worth $308,812,000 after purchasing an additional 596,056 shares in the last quarter. Finally, Bank of Nova Scotia boosted its position in shares of HCA Healthcare by 505.0% during the 4th quarter. Bank of Nova Scotia now owns 557,426 shares of the company’s stock worth $69,368,000 after purchasing an additional 465,293 shares in the last quarter. Hedge funds and other institutional investors own 71.66% of the company’s stock.
HCA has been the topic of several research analyst reports. SunTrust Banks boosted their target price on shares of HCA Healthcare to $175.00 and gave the stock a “buy” rating in a research report on Wednesday, January 30th. Zacks Investment Research upgraded shares of HCA Healthcare from a “hold” rating to a “buy” rating and set a $139.00 target price on the stock in a research report on Friday, May 3rd. UBS Group boosted their target price on shares of HCA Healthcare from $164.00 to $172.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Deutsche Bank boosted their target price on shares of HCA Healthcare from $160.00 to $165.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Finally, Jefferies Financial Group set a $158.00 target price on shares of HCA Healthcare and gave the stock a “buy” rating in a research report on Wednesday, April 17th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and nineteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $149.41.
HCA Healthcare (NYSE:HCA) last released its quarterly earnings results on Tuesday, April 30th. The company reported $2.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.31 by $0.66. The business had revenue of $12.52 billion during the quarter, compared to the consensus estimate of $12.34 billion. HCA Healthcare had a negative return on equity of 112.65% and a net margin of 7.71%. The business’s revenue was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.18 EPS. Research analysts forecast that HCA Healthcare Inc will post 10.38 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 3rd will be paid a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 1.30%. The ex-dividend date is Friday, May 31st. HCA Healthcare’s dividend payout ratio (DPR) is presently 16.38%.
In other news, insider Jon M. Foster sold 44,281 shares of HCA Healthcare stock in a transaction on Friday, May 10th. The stock was sold at an average price of $122.28, for a total transaction of $5,414,680.68. Following the completion of the transaction, the insider now owns 96,052 shares of the company’s stock, valued at approximately $11,745,238.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 2.70% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This story was originally posted by Week Herald and is owned by of Week Herald. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://weekherald.com/2019/05/16/boston-partners-has-5-40-million-position-in-hca-healthcare-inc-hca.html.
HCA Healthcare Company Profile
HCA Healthcare, Inc, through its subsidiaries, provides health care services. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy services.
Further Reading: What is the NASDAQ?
Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare Inc (NYSE:HCA).
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.